CG-806

· Aptose Biosciences Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CG-806, covering 2025-03-07 to 2025-03-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]